PubRank

Justin C McArthur

Author PubWeight™ 153.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2010 7.56
2 Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008 6.91
3 The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007 5.18
4 The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005 4.48
5 HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002 4.20
6 Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010 2.91
7 Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009 2.88
8 Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology 2012 2.30
9 Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 2006 2.27
10 A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis 2005 2.25
11 Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009 2.14
12 An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007 1.94
13 The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004 1.90
14 Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004 1.87
15 Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 2012 1.79
16 Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002 1.68
17 HIV-associated sensory neuropathies. AIDS 2002 1.65
18 Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr 2013 1.64
19 A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology 2013 1.62
20 Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol 2011 1.57
21 Clinical validation of the NeuroScreen. J Neurovirol 2005 1.57
22 HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 2010 1.56
23 Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002 1.56
24 Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011 1.53
25 Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 2004 1.49
26 Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read 2005 1.46
27 Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009 1.45
28 Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol 2002 1.43
29 Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol 2008 1.40
30 Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003 1.39
31 Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005 1.39
32 Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006 1.33
33 Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 2005 1.32
34 Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol 2005 1.23
35 HIV-associated opportunistic infections of the CNS. Lancet Neurol 2012 1.22
36 Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain 2007 1.21
37 Sleep, function and HIV: a multi-method assessment. AIDS Behav 2013 1.20
38 Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 2007 1.15
39 Saving the clinician-scientist: report of the ANA long range planning committee. Ann Neurol 2006 1.12
40 Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol 2011 1.12
41 Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002 1.11
42 Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003 1.11
43 Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008 1.10
44 Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009 1.09
45 Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002 1.09
46 Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008 1.08
47 Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 2006 1.08
48 Epidermal reinnervation after intracutaneous axotomy in man. J Comp Neurol 2003 1.08
49 Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol 2005 1.08
50 Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology 2005 1.07
51 Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol 2007 1.06
52 Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis 2006 1.06
53 Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy. Brain 2011 1.05
54 Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol 2005 1.04
55 Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. J Neurol Sci 2011 1.02
56 HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 2012 1.01
57 Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol 2006 1.01
58 Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care 2011 1.01
59 Recent developments in the HIV neuropathies. Curr Opin Neurol 2003 1.00
60 Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012 0.99
61 Progression of HIV-associated dementia treated with HAART. AIDS Read 2002 0.98
62 Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2006 0.98
63 Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am J Pathol 2011 0.97
64 CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J 2009 0.97
65 Predictors of outcome in acute encephalitis. Neurology 2013 0.97
66 A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One 2007 0.97
67 Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006 0.96
68 Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons. J Acquir Immune Defic Syndr 2013 0.95
69 Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 2012 0.95
70 FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003 0.95
71 Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009 0.95
72 Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr 2013 0.93
73 Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Res Hum Retroviruses 2008 0.93
74 Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology 2012 0.93
75 Aquaporin 4 is increased in association with human immunodeficiency virus dementia: implications for disease pathogenesis. J Neurovirol 2005 0.93
76 The sleep-immunity relationship. Neurol Clin 2012 0.93
77 Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci 2008 0.92
78 Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. J Neurovirol 2010 0.92
79 The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007 0.91
80 Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 2013 0.91
81 The evaluation and diagnosis of "insomnia" in relation to sleep disturbance prevalence and impact in early-treated HIV-infected persons. Clin Infect Dis 2012 0.91
82 NeuroAIDS, drug abuse, and inflammation: building collaborative research activities. J Neuroimmune Pharmacol 2006 0.91
83 Altered cutaneous nerve regeneration in a simian immunodeficiency virus / macaque intracutaneous axotomy model. J Comp Neurol 2009 0.90
84 Amyloid precursor protein expression in circulating monocytes and brain macrophages from patients with HIV-associated cognitive impairment. J Neuroimmunol 2004 0.89
85 Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics 2012 0.89
86 Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals. J Neurovirol 2011 0.87
87 Through a glass, darkly: cerebrospinal fluid viral load measurements and the pathogenesis of human immunodeficiency virus infection of the central nervous system. Arch Neurol 2002 0.86
88 Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol 2012 0.85
89 Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol 2012 0.85
90 Older individuals with HIV infection have greater memory deficits than younger individuals. J Neurovirol 2013 0.85
91 Stroke incidentally identified using improved positron emission tomography for microglial activation. Arch Neurol 2009 0.84
92 Simplification of the research diagnosis of HIV-associated sensory neuropathy. HIV Clin Trials 2009 0.84
93 Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS 2015 0.83
94 SIV-induced impairment of neurovascular repair: a potential role for VEGF. J Neurovirol 2012 0.83
95 Serum matrix metalloproteinase levels correlate with brain injury in human immunodeficiency virus infection. J Neurovirol 2009 0.83
96 Marked relationship between matrix metalloproteinase 7 and brain atrophy in HIV infection. J Neurovirol 2011 0.82
97 Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation. J Neurovirol 2007 0.82
98 Ethnic differences in epidermal nerve fiber density. Muscle Nerve 2013 0.81
99 Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology 2012 0.81
100 Brainstem encephalitis: etiologies, treatment, and predictors of outcome. J Neurol 2013 0.81
101 HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol 2016 0.80
102 A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. J Neurovirol 2013 0.80
103 Neuroinflammation and virus replication in the spinal cord of simian immunodeficiency virus-infected macaques. J Neuropathol Exp Neurol 2015 0.80
104 Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy. AIDS 2014 0.80
105 Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. J Neurovirol 2014 0.79
106 The armadillo as a model for peripheral neuropathy in leprosy. ILAR J 2014 0.79
107 The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol 2014 0.79
108 Another tool for the neurologist's toolbox. Ann Neurol 2005 0.79
109 Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler 2011 0.78
110 AIDS dementia complex in China. J Clin Neurosci 2006 0.78
111 Is the glass three-quarters full or one-quarter empty? J Infect Dis 2006 0.78
112 Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS 2012 0.77
113 Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis 2003 0.77
114 The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations. J Pain 2017 0.75
115 Reply: To PMID 23722610. J Acquir Immune Defic Syndr 2014 0.75
116 Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology 2012 0.75
117 Clinical reasoning: Multiple cranial neuropathies in a young man. Neurology 2013 0.75
118 CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder. Curr Biomark Find 2012 0.75
119 Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. AIDS 2017 0.75
120 Informatic interrogation of CSF proteomic profiles from HIV-infected subjects implicates acute phase and complement systems in shifting cognitive status. AIDS 2017 0.75